论文部分内容阅读
FK506是一种实验免疫抑制剂。1989年2月,一名28岁曾因慢性排斥而失去2个移植物且有肾衰(可能是环孢菌素所致)的女性患者,在美国第一次接受了FK506。患者在第三次肝移植后,给予环孢菌素和FK506。几天后,主诉头痛、恶心并呕吐。医生怀疑多种药物反应并注意到患者对环孢菌素耐受差,而只用FK506。48h后,患者症状消退。之后2周排斥作用消失,新植肝功能改善。一个月后,患者受损肾脏用移植物取代。患者在恢复后的第二个月回家且新植的肝、肾具有功能。
FK506 is an experimental immunosuppressant. In February 1989, a 28-year-old female patient who had lost 2 grafts due to chronic rejection and had kidney failure (probably due to cyclosporine) received FK506 for the first time in the United States. Patients received cyclosporine and FK506 after the third liver transplant. A few days later, the chief complaint was headache, nausea and vomiting. Doctors suspect multiple drug reactions and noticed that patients have poor tolerance to cyclosporine, and the symptoms subsided only after FK506.48h. After 2 weeks the exclusion disappeared, new liver function improved. A month later, the patient’s damaged kidney was replaced with a graft. The patient returns home the second month after recovery and the newly planted liver and kidney function.